{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:49:29Z","timestamp":1758635369488,"version":"3.41.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Japanese Foundation for the Multidisciplinary Treatment of Cancer."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1245\/s10434-025-17661-7","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:12:55Z","timestamp":1750867975000},"page":"6561-6570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02): A Phase 2 Clinical Trial"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-1199","authenticated-orcid":false,"given":"Minoru","family":"Kitago","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Aiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sojun","family":"Hoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Itano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"Suppl 2","key":"17661_CR1","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.21037\/jgo-20-118","volume":"12","author":"R Ranganath","year":"2021","unstructured":"Ranganath R, Chu Q. Global trends in pancreas cancer among Asia-Pacific population. J Gastrointest Oncol. 2021;12(Suppl 2):S374\u201386.","journal-title":"J Gastrointest Oncol."},{"key":"17661_CR2","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin."},{"issue":"Suppl 5","key":"17661_CR3","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56\u201368.","journal-title":"Ann Oncol."},{"key":"17661_CR4","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473\u201381.","journal-title":"JAMA."},{"key":"17661_CR5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/sj.bjc.6605256","volume":"101","author":"H Ueno","year":"2009","unstructured":"Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908\u201315.","journal-title":"Br J Cancer."},{"key":"17661_CR6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324.","journal-title":"Lancet."},{"key":"17661_CR7","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med."},{"key":"17661_CR8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357.","journal-title":"Lancet."},{"key":"17661_CR9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","volume":"28","author":"T Okusaka","year":"2023","unstructured":"Okusaka T, Nakamura M, Yoshida M, et al. Clinical practice guidelines for pancreatic cancer 2022 from the Japan Pancreas society: a synopsis. Int J Clin Oncol. 2023;28:493\u2013511.","journal-title":"Int J Clin Oncol."},{"issue":"Suppl 1","key":"17661_CR10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000051469","volume":"60","author":"S Takahashi","year":"1999","unstructured":"Takahashi S, Aiura K, Saitoh J, Hayatsu S, Kitajima M, Ogata Y. Treatment strategy for pancreatic head cancer: pylorus-preserving pancreatoduodenectomy, intraoperative radiotherapy and portal catheterization. Digestion. 1999;60(Suppl 1):130\u20134.","journal-title":"Digestion."},{"key":"17661_CR11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000244265","volume":"10","author":"K Aiura","year":"2010","unstructured":"Aiura K, Takahashi S, Matsui J, Ueda M, Kitagawa Y. Beneficial effects of 5-fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer. Pancreatology. 2010;10:250\u20138.","journal-title":"Pancreatology."},{"key":"17661_CR12","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/cam4.1178","volume":"6","author":"Y Nakano","year":"2017","unstructured":"Nakano Y, Kitago M, Shinoda M, et al. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Cancer Med. 2017;6:2278\u201386.","journal-title":"Cancer Med."},{"key":"17661_CR13","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035856","volume":"102","author":"K Hayashi","year":"2023","unstructured":"Hayashi K, Kitago M, Abe Y, et al. Long-term survival after surgical resection for bone metastasis from pancreatic cancer: a case report. Medicine (Baltimore). 2023;102:e35856.","journal-title":"Medicine (Baltimore)."},{"key":"17661_CR14","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7459","volume":"13","author":"M Kitago","year":"2024","unstructured":"Kitago M, Endo Y, Aiura K, et al. Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. Cancer Med. 2024;13:e7459.","journal-title":"Cancer Med."},{"key":"17661_CR15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00280-012-2029-1","volume":"71","author":"Y Murakami","year":"2013","unstructured":"Murakami Y, Uemura K, Sudo T, et al. Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol. 2013;71:419\u201329.","journal-title":"Cancer Chemother Pharmacol."},{"key":"17661_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187\u201396.","journal-title":"Ann Surg."},{"key":"17661_CR17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.surg.2016.11.014","volume":"161","author":"C Bassi","year":"2017","unstructured":"Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584\u201391.","journal-title":"Surgery."},{"key":"17661_CR18","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","volume":"2","author":"W Hryniuk","year":"1984","unstructured":"Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281\u20138.","journal-title":"J Clin Oncol."},{"key":"17661_CR19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004282","volume":"95","author":"N Yabusaki","year":"2016","unstructured":"Yabusaki N, Fujii T, Yamada S, et al. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity. Medicine (Baltimore). 2016;95:e4282.","journal-title":"Medicine (Baltimore)."},{"key":"17661_CR20","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/SLA.0000000000002734","volume":"269","author":"VP Groot","year":"2019","unstructured":"Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269:1154\u201362.","journal-title":"Ann Surg."},{"key":"17661_CR21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MPA.0000000000001513","volume":"49","author":"T Okusaka","year":"2020","unstructured":"Okusaka T, Nakamura M, Yoshida M, et al. Clinical practice guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: a synopsis. Pancreas. 2020;49:326\u201335.","journal-title":"Pancreas."},{"key":"17661_CR22","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.22.01134","volume":"41","author":"MA Tempero","year":"2023","unstructured":"Tempero MA, Pelzer U, O\u2019Reilly EM, et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol. 2023;41:2007\u201319.","journal-title":"J Clin Oncol."},{"key":"17661_CR23","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100841","volume":"34","author":"H Tang","year":"2022","unstructured":"Tang H, Qiao C, Lu J, et al. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: retrospective real-world data. Neoplasia. 2022;34:100841.","journal-title":"Neoplasia."},{"key":"17661_CR24","doi-asserted-by":"crossref","first-page":"1276037","DOI":"10.3389\/fonc.2023.1276037","volume":"13","author":"H Li","year":"2023","unstructured":"Li H, Guo Y, Sun X, et al. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study. Front Oncol. 2023;13:1276037.","journal-title":"Front Oncol."},{"key":"17661_CR25","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.21873\/anticanres.15802","volume":"42","author":"H Matsushima","year":"2022","unstructured":"Matsushima H, Adachi T, Hidaka M, et al. Prognostic impact of relative dose intensity of adjuvant chemotherapy with S-1 on pancreatic ductal adenocarcinoma. Anticancer Res. 2022;42:3133\u201341.","journal-title":"Anticancer Res."},{"key":"17661_CR26","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3390\/cancers16050922","volume":"16","author":"N Funamizu","year":"2024","unstructured":"Funamizu N, Sakamoto A, Hikida T, et al. C-reactive protein-to-albumin ratio to predict tolerability of S-1 as an adjuvant chemotherapy in pancreatic cancer. Cancers (Basel). 2024;16:922.","journal-title":"Cancers (Basel)."},{"key":"17661_CR27","first-page":"e196","volume":"52","author":"A Sakamoto","year":"2023","unstructured":"Sakamoto A, Funamizu N, Shine M, et al. Geriatric nutritional risk index predicts tolerability of S-1 as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Pancreas. 2023;52:e196\u2013202.","journal-title":"Pancreas."},{"key":"17661_CR28","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1007\/s10147-023-02399-7","volume":"28","author":"H Kayashima","year":"2023","unstructured":"Kayashima H, Itoh S, Shimokawa M, et al. Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoperative adjuvant chemotherapy S-1 (PACS-1) trial. Int J Clin Oncol. 2023;28:1520\u20139.","journal-title":"Int J Clin Oncol."},{"key":"17661_CR29","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936\u201345.","journal-title":"Ann Surg."},{"key":"17661_CR30","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/bjs.11295","volume":"106","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Mihaljevic AL, Probst P, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019;106:1590\u2013601.","journal-title":"Br J Surg."},{"key":"17661_CR31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s11605-012-1859-9","volume":"16","author":"T Sugiura","year":"2012","unstructured":"Sugiura T, Uesaka K, Kanemoto H, et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:977\u201385.","journal-title":"J Gastrointest Surg."},{"key":"17661_CR32","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.3390\/cancers14194605","volume":"14","author":"AS Mehdorn","year":"2022","unstructured":"Mehdorn AS, Gemoll T, Busch H, et al. Biomarkers in liquid biopsies for prediction of early liver metastases in pancreatic cancer. Cancers (Basel). 2022;14:4605.","journal-title":"Cancers (Basel)."},{"key":"17661_CR33","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ags3.12597","volume":"6","author":"T Hata","year":"2022","unstructured":"Hata T, Chiba K, Mizuma M, et al. Levels of tumor markers CEA\/CA 19\u20139 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer. Ann Gastroenterol Surg. 2022;6:862\u201372.","journal-title":"Ann Gastroenterol Surg."},{"key":"17661_CR34","doi-asserted-by":"crossref","first-page":"e1278","DOI":"10.1097\/SLA.0000000000005395","volume":"277","author":"K Omiya","year":"2023","unstructured":"Omiya K, Oba A, Inoue Y, et al. Serum DUPAN-2 could be an alternative biological marker for CA19-9 nonsecretors with pancreatic cancer. Ann Surg. 2023;277:e1278\u201383.","journal-title":"Ann Surg."},{"key":"17661_CR35","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/bjc.2017.479","volume":"118","author":"Y Nakano","year":"2018","unstructured":"Nakano Y, Kitago M, Matsuda S, et al. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. Br J Cancer. 2018;118:662\u20139.","journal-title":"Br J Cancer."},{"key":"17661_CR36","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1111\/cas.14425","volume":"111","author":"T Yokose","year":"2020","unstructured":"Yokose T, Kitago M, Matsuda S, et al. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. Cancer Sci. 2020;111:2174\u201382.","journal-title":"Cancer Sci."},{"key":"17661_CR37","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00432-021-03541-6","volume":"147","author":"Y Endo","year":"2021","unstructured":"Endo Y, Fujimoto M, Ito N, et al. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methylation profiling. J Cancer Res Clin Oncol. 2021;147:1341\u201354.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"11","key":"17661_CR38","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1111\/cas.16341","volume":"115","author":"S Uemura","year":"2024","unstructured":"Uemura S, Kabe Y, Kitago M, et al. Prognosis prediction of PDAC via detection of O-glycan altered extracellular vesicles in perioperative sera. Cancer Sci. 2024;115(11):3718\u201328.","journal-title":"Cancer Sci."},{"issue":"1","key":"17661_CR39","doi-asserted-by":"crossref","first-page":"21732","DOI":"10.1038\/s41598-024-72569-8","volume":"14","author":"G Shimane","year":"2024","unstructured":"Shimane G, Nakano Y, Matsuda S, et al. Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma. Sci Rep. 2024;14(1):21732.","journal-title":"Sci Rep."},{"key":"17661_CR40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3748\/wjg.v27.i3.294","volume":"27","author":"H Kojima","year":"2021","unstructured":"Kojima H, Kitago M, Iwasaki E, et al. Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: a case report and literature review. World J Gastroenterol. 2021;27:294\u2013304.","journal-title":"World J Gastroenterol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17661-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:01:30Z","timestamp":1754150490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17661-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["17661"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17661-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported via the Japanese Foundation for the Multidisciplinary Treatment of Cancer. Dr. Kitagawa reports grants and personal fees from TSUMURA & CO.; grants and personal fees from Kowa Company, Ltd.; grants and personal fees from Eisai Co., Ltd.; grants and personal fees from Takeda Pharmaceutical Company Limited; grants and personal fees from KAKEN PHARMACEUTICAL CO., LTD.; grants and personal fees from Otsuka Pharmaceutical Factory, Inc.; grants and personal fees from TAIHO PHARMACEUTICAL CO., LTD; grants and personal fees from CHUGAI PHARMACEUTICAL CO., LTD.; grants and personal fees from ASAHI KASEI PHARMA CORPORATION; personal fees from AstraZeneca K.K.; personal fees from Ethicon Inc.; personal fees from ONO PHARMACEUTICAL CO., LTD.; personal fees from Olympus Corporation; personal fees from Cardinal Health K.K.; personal fees from SHIONOGI & CO., LTD.; personal fees from Bristol-Myers Squibb K.K.; personal fees from MSD K.K.; personal fees from Smith & Nephew K.K.; personal fees from ASKA Pharmaceutical Co., Ltd.; personal fees from MIYARISAN PHARMACEUTICAL CO. LTD.; personal fees from Toray Industries, Inc.; personal fees from DAIICHI SANKYO COMPANY, LIMITED; personal fees from Chugai Foundation for Innovative Drug Discovery Science; personal fees from Nippon Kayaku Co., Ltd.; personal fees from EA Pharma Co., Ltd.,; personal fees from Intuitive Surgical G.K.; personal fees from SYSMEX CORPORATION; personal fees from AI Medical Service Inc.; grants from Otsuka Pharmaceutical Co., Ltd.; grants from Sumitomo Pharma Co., Ltd.; grants from Kyouwa Hakkou Kirin Co., Ltd.; grants from TEIJIN PHARMA LIMITED; and grants from Nippon Covidien Inc. outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial Disclosures"}}]}}